Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions


Por: Villatoro, S, Mayo-de-las-Casas, C, Jordana-Ariza, N, Viteri-Ramirez, S, Garzon-Ibanez, M, Moya-Horno, I, Garcia-Pelaez, B, Gonzalez-Cao, M, Malapelle, U, Balada-Bel, A, Martinez-Bueno, A, Campos, R, Reguart, N, Majem, M, Blanco, R, Blasco, A, Catalan, MJ, Gonzalez, X, Troncone, G, Karachaliou, N, Rosell, R and Molina-Vila, MA

Publicada: 1 dic 2019 Ahead of Print: 1 oct 2019
Resumen:
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations and guide treatment decisions. We collected 42 CSF, PE, and ASC samples from advanced non-small-cell lung cancer and melanoma patients. Cell-free DNA (cfDNA) was purified and driver mutations analyzed and quantified by PNA-Q-PCR or next-generation sequencing. All 42 fluid samples were evaluable; clinically relevant mutations were detected in 41 (97.6%). Twenty-three fluids had paired blood samples, 22 were mutation positive in fluid but only 14 in blood, and the abundance of the mutant alleles was significantly higher in fluids. Of the 34 fluids obtained at progression to different therapies, EGFR resistance mutations were detected in nine and ALK acquired mutations in two. The results of testing of CSF, PE, and ASC were used to guide treatment decisions, such as initiation of osimertinib treatment or selection of specific ALK tyrosine-kinase inhibitors. In conclusion, fluids close to metastatic sites are superior to blood for the detection of relevant mutations and can offer valuable clinical information, particularly in patients progressing to targeted therapies.

Filiaciones:
Villatoro, S:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Mayo-de-las-Casas, C:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Jordana-Ariza, N:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Viteri-Ramirez, S:
 Quiron Dexeus Univ Hosp, Dr Rosell Oncol Inst, Barcelona, Spain

Garzon-Ibanez, M:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Moya-Horno, I:
 Gen Hosp Catalonia, Dr Rosell Oncol Inst, Sant Cugat Del Valles, Spain

Garcia-Pelaez, B:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Gonzalez-Cao, M:
 Quiron Dexeus Univ Hosp, Dr Rosell Oncol Inst, Barcelona, Spain

Malapelle, U:
 Univ Naples Federico II, Dept Publ Hlth, Naples, Italy

Balada-Bel, A:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Martinez-Bueno, A:
 Quiron Dexeus Univ Hosp, Dr Rosell Oncol Inst, Barcelona, Spain

Campos, R:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Reguart, N:
 Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

Majem, M:
 Hosp Santa Creu & Sant Pau, Med Oncol Serv, Barcelona, Spain

Blanco, R:
 Hosp Terrassa, Med Oncol Serv, Barcelona, Spain

Blasco, A:
 Hosp Gen Univ Valencia, Med Oncol Dept, Valencia, Spain

Catalan, MJ:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

Gonzalez, X:
 Gen Hosp Catalonia, Dr Rosell Oncol Inst, Sant Cugat Del Valles, Spain

Troncone, G:
 Univ Naples Federico II, Dept Publ Hlth, Naples, Italy

Karachaliou, N:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

 Univ Hosp Sagrat Cor, Dr Rosen Oncol Inst, Barcelona, Spain

:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain

 Quiron Dexeus Univ Hosp, Dr Rosell Oncol Inst, Barcelona, Spain

 Germans Trias & Pujol Hlth Sci Inst & Hosp, Catalan Inst Oncol, Canc Biol & Precis Med Program, Badelona, Spain

Molina-Vila, MA:
 Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Extemal Consultat Bldg,Room 1-7, Barcelona 08028, Spain
ISSN: 15747891





Molecular Oncology
Editorial
John Wiley and Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Países Bajos
Tipo de documento: Article
Volumen: 13 Número: 12
Páginas: 2633-2645
WOS Id: 000492260800001
ID de PubMed: 31529604
imagen gold, Green Published

MÉTRICAS